Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mu Sun

Showing results (301-310 of 338) with videos related to

Pageof 34
Sort By:
Cancer|June 8, 2012
Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trialJong-Mu Sun, Ki Hyeong Lee, Sang-We Kim, et al.
The Journal of Molecular Diagnostics : JMD|December 19, 2012
Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancerMaruja E Lira, Tae Min Kim, Donghui Huang, et al.
Oncotarget|May 7, 2017
Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center's experiencesMinho Cho, Soomin Ahn, Mineui Hong, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|June 26, 2021
Therapeutic efficacy of cancer vaccine adjuvanted with nanoemulsion loaded with TLR7/8 agonist in lung cancer modelJiae Koh, Sohyun Kim, Sang Nam Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2024
Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer (BLOSSOM)Sehhoon Park, Richard Baldry, Hyun Ae Jung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2026
JIN-A02, a Mutant-Selective Fourth-Generation EGFR inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLCEun Ji Lee, Ji Ae Ko, Min-Je Kim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 12, 2023
Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non-Small Cell Lung CancerHyun-Ae Jung, Bo Mi Ku, Yeon Jeong Kim, et al.
Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi|February 13, 2014
[Investigation on measles cases of new genotype D8 in Beijing, 2013]Juan Li, Li Lu, Rui Ma, et al.
The Lancet. Oncology|December 24, 2011
Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 studyJeeyun Lee, Se Hoon Park, Heung-Moon Chang, et al.
Journal for Immunotherapy of Cancer|October 31, 2025
Artificial intelligence-powered spatial analysis of tumor microenvironment in patients with non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitorYeong Hak Bang, Geun-Ho Park, Jin Woo Oh, et al.
Pageof 34

Showing results (301-310 of 338) with videos related to

Sort By:
Pageof 34
Cancer|June 8, 2012
Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trialJong-Mu Sun, Ki Hyeong Lee, Sang-We Kim, et al.
The Journal of Molecular Diagnostics : JMD|December 19, 2012
Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancerMaruja E Lira, Tae Min Kim, Donghui Huang, et al.
Oncotarget|May 7, 2017
Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center's experiencesMinho Cho, Soomin Ahn, Mineui Hong, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|June 26, 2021
Therapeutic efficacy of cancer vaccine adjuvanted with nanoemulsion loaded with TLR7/8 agonist in lung cancer modelJiae Koh, Sohyun Kim, Sang Nam Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2024
Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer (BLOSSOM)Sehhoon Park, Richard Baldry, Hyun Ae Jung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2026
JIN-A02, a Mutant-Selective Fourth-Generation EGFR inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLCEun Ji Lee, Ji Ae Ko, Min-Je Kim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 12, 2023
Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non-Small Cell Lung CancerHyun-Ae Jung, Bo Mi Ku, Yeon Jeong Kim, et al.
Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi|February 13, 2014
[Investigation on measles cases of new genotype D8 in Beijing, 2013]Juan Li, Li Lu, Rui Ma, et al.
The Lancet. Oncology|December 24, 2011
Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 studyJeeyun Lee, Se Hoon Park, Heung-Moon Chang, et al.
Journal for Immunotherapy of Cancer|October 31, 2025
Artificial intelligence-powered spatial analysis of tumor microenvironment in patients with non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitorYeong Hak Bang, Geun-Ho Park, Jin Woo Oh, et al.
Pageof 34